- 1988 - Cetus Corporation, Emeryville, CA establishes its European headquarters, EuroCetus B.V. in Amsterdam, the Netherlands.
- 1990-1991 - EuroCetus facility licensed for production and release of ProLeukin (IL-2) for Europe and rest of World except USA and Japan.
- 1992 – Chiron Corporation acquires Cetus Corporation. Eurocetus B.V. becomes Chiron B.V.
- 1996 – Facility licensed for commercial production of Pertussis vaccine.
- 1997 – Facility licensed by WHO for commercial production of Meningitis A polysaccharides.
- 1997-1999 – Facility licensed by UK, MCA and Italian Health Branch for Meningitis C polysaccharide and CRM197 carrier protein for conjugated vaccine Menjugate®.
- 2000 – Facility acquired by Dr William J. Rutter. SynCo Bio Partners B.V. established.
- 2001 – Facility licensed by EMEA and Health Canada for Meningitis C Polysaccharides and CRM197 carrier protein for Menjugate® production.
- 2005 – Expansion of GMP facilities to allow production of a wider range of protein, polysaccharide and live biotherapeutic products.
- 2008 - Expansion of process development capabilities to enable a greater range of projects to be completed
- 2008 - Facility licensed by Korean FDA for commercial production
- 2009 - Facility licensed by ANVISA for commercial production
- 2009 - SynCo wins 'Best Contract Manufacturing Organisation 2009' Vie award
- 2010 - SynCo shortlisted for 'Best Contract Manufacturing Organisation 2010' Vie award